Sumitomo Mitsui Trust Holdings Inc. Grows Stock Position in Cerus Co. (NASDAQ:CERS)

Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Cerus Co. (NASDAQ:CERS) by 69.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,544,276 shares of the biotechnology company’s stock after buying an additional 3,494,891 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 6.09% of Cerus worth $44,046,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Envestnet Asset Management Inc. raised its stake in Cerus by 9.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 27,477 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 2,455 shares during the last quarter. Raymond James Trust N.A. raised its stake in Cerus by 13.6% in the 3rd quarter. Raymond James Trust N.A. now owns 25,000 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 3,000 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Cerus by 8.5% in the 3rd quarter. Janney Montgomery Scott LLC now owns 54,200 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 4,250 shares during the last quarter. Aperio Group LLC acquired a new position in Cerus in the 2nd quarter valued at about $27,000. Finally, Prudential Financial Inc. raised its stake in Cerus by 20.7% in the 2nd quarter. Prudential Financial Inc. now owns 34,297 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 5,880 shares during the last quarter. Institutional investors and hedge funds own 74.26% of the company’s stock.

Several research analysts recently weighed in on the stock. Stephens assumed coverage on shares of Cerus in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $8.00 target price for the company. Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a research note on Monday, October 7th. ValuEngine downgraded shares of Cerus from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub downgraded shares of Cerus from a “sell” rating to a “strong sell” rating in a research note on Friday, October 25th. Finally, Stifel Nicolaus assumed coverage on shares of Cerus in a research note on Tuesday, August 27th. They issued a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $7.63.

In other news, Director Timothy B. Anderson sold 9,664 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $5.25, for a total transaction of $50,736.00. Following the completion of the transaction, the director now owns 177,649 shares of the company’s stock, valued at approximately $932,657.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Carol Moore sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $5.33, for a total transaction of $159,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 58,459 shares of company stock valued at $312,129. Corporate insiders own 7.26% of the company’s stock.

NASDAQ CERS opened at $4.24 on Friday. Cerus Co. has a 12 month low of $3.95 and a 12 month high of $6.88. The company has a 50-day moving average of $4.63 and a 200-day moving average of $5.17. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.77 and a quick ratio of 2.31. The company has a market cap of $607.59 million, a P/E ratio of -9.64 and a beta of 1.60.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $17.69 million. During the same period in the prior year, the company earned ($0.11) EPS. The company’s revenue was up 16.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Cerus Co. will post -0.5 EPS for the current year.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Read More: Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply